ANIP has shown strong sales growth, especially in generics and rare disease segments, but faces persistent margin compression ...

The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina represents a ...

Truist Financial analyst Les Sulewski maintained a Hold rating on ANI Pharmaceuticals today and set a price target of $66.77. The company’s shares closed yesterday at $66.77. Take advantage of ...